Arrowhead Pharmaceuticals, Inc. (ARWR)
$26.15
+5.1
(+24.23%)▲
Arrowhead Pharmaceuticals, Inc. Key Statistics
Market Capitalization | $3.3B |
Revenue TTM | $19.6M |
EBITDA | $-529.8M |
Earnings Per Share (EPS) | $-5.0 |
Profit Margin | 0.0% |
Quarterly Earnings Growth YOY | 0.1% |
Return On Equity TTM | -151.84% |
Arrowhead Pharmaceuticals, Inc. share price movements
- $22.33$26.59$26.15
14.6%
Downside
Day's Volatility :16.01%
Upside
1.65%
- $17.05$39.83$26.15
34.8%
Downside
52 Weeks Volatility :57.19%
Upside
34.35%
Arrowhead Pharmaceuticals, Inc. Returns
| Period | Arrowhead Pharmaceuticals, Inc. | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 8.6% | -5.9% | 0.0% |
6 Months | 14.34% | 3.8% | 0.0% |
1 Year | -9.77% | 13.3% | 0.0% |
3 Years | -63.26% | 11.0% | -21.1% |
Analyst Recommendation on Arrowhead Pharmaceuticals, Inc.
- Current
- 1M Ago
- 3M Ago
Analyst Forecast on Arrowhead Pharmaceuticals, Inc.
What analysts predicted
Upside of 73.55%
Insights on Arrowhead Pharmaceuticals, Inc.
Decreasing Revenue
Revenue is down for the last 2 quarters, 16.09M → 3.55M (in $), with an average decrease of 77.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -125.3M → -170.79M (in $), with an average decrease of 36.3% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 54.7% return, outperforming this stock by 64.5%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 40.4% return, outperforming this stock by 103.7%
Arrowhead Pharmaceuticals, Inc. Technicals Summary
Sell
Neutral
Buy
Arrowhead Pharmaceuticals, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Arrowhead Pharmaceuticals, Inc. Vs Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Arrowhead Pharmaceuticals, Inc. | 30.88% | 14.34% | -9.77% | -63.26% | -64.18% |
 Regeneron Pharmaceuticals, Inc. | -18.6% | -21.9% | -6.64% | 15.35% | 104.57% |
 Biontech Se | 5.89% | 29.49% | 21.63% | -66.7% | 449.23% |
 Alnylam Pharmaceuticals, Inc. | -10.87% | 72.69% | 54.71% | 40.39% | 116.61% |
 Vertex Pharmaceuticals Incorporated | -1.23% | 5.31% | 32.35% | 144.36% | 109.5% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Arrowhead Pharmaceuticals, Inc. | NA | NA | -1.32 | -4.53 | -1.52 | -0.41 | NA | 2.66 |
Regeneron Pharmaceuticals, Inc. | 18.66 | 18.66 | 1.12 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.06 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.22 | 0.54 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Arrowhead Pharmaceuticals, Inc. | Buy | $3.3B | -64.18% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $83.0B | 104.57% | 18.66 | 33.61% |
Biontech Se | Buy | $28.9B | 449.23% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $31.6B | 116.61% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $119.6B | 109.5% | 32.84 | -4.51% |
Arrowhead Pharmaceuticals, Inc. Institutional Holdings
BlackRock Inc
12.62%Vanguard Group Inc
9.84%venBio Select Advisor LLC
7.15%FMR Inc
4.88%State Street Corp
4.70%Slate Path Capital LP
3.93%
Corporate Announcements
Arrowhead Pharmaceuticals, Inc. Earnings
Arrowhead Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None
Read More
About Arrowhead Pharmaceuticals, Inc.
arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Organization | Arrowhead Pharmaceuticals, Inc. |
Employees | 525 |
CEO | Dr. Christopher R. Anzalone Ph.D. |
Industry | Health Technology |
